Pharmafile Logo

Hospira

Novartis day

Novartis pulls ahead of Merck in MET-positive lung cancer race

FDA starts priority review of Swiss pharma's MET inhibitor

- PMLiVE

Biogen triumphs over Mylan’s Tecfidera patent challenge

Shares in Biogen skyrocketed by 32% following ruling

- PMLiVE

GSK considers more divestments to help R&D push

Turns priority to future growth drivers and R&D investment

- PMLiVE

Novartis faces criticism over Zolgensma ‘health lottery’

SMA Europe deems access programme 'inappropriate'

Lighthouse Medical Communications US – An opportunity of a lifetime to be part of the Lucid Group magic

Our family at Lighthouse Medical Communications US are looking for talented individuals to join its team in hashtagManhattan. If you want to be part of something magical get in touch...

Lucid Group Communications Limited

- PMLiVE

Will biosimilars ever catch on in the US?

Why biosimilars are viewed in the US as ‘me too’ drugs rather than as just-as-good alternatives to branded products

- PMLiVE

Roche posts minor sales miss in Q4 as biosimilar pressure grows

Swiss pharma still managed an 8% increase in pharma sales

- PMLiVE

Vyndaqel a bright spot as Pfizer comes under pressure

Faces a challenging period as big brands experience a slowdown

Novartis day

Cosentyx, Entresto drive topline growth for Novartis in Q4

Overall net income fell for the full year compared to 2018

- PMLiVE

Novartis gets EU approval for multiple sclerosis therapy Mayzent

Offers subgroup of patients an important new treatment option

- PMLiVE

AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

Outperformed rival across all primary and secondary endpoints

- PMLiVE

Novartis links up with NHS for speedy access to cholesterol drug inclisiran

Collaboration will see drug offered to patients across the UK via clinical study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links